When Eli Lilly developed Retatrutide, they weren't just creating another metabolic research compound. They were building something structurally distinct from everything the field had seen before. As the first triple receptor agonist to simultaneously target GLP-1, GIP, and glucagon receptors in a single 39-amino acid molecule, Retatrutide opened a new chapter in how researchers model complex...
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek